London-based private equity firm CVC Capital Partners, European buyout firm Cinven and London-based Advent Venture Partners are all in the running for a stake in Turkish drug maker Bilim Ilac, Reuters said. The size of the potential deal is unclear.
(Reuters) – Three private equity funds including London-based CVC Capital Partners with Turkish fellow investor Turkven are among potential buyers for a stake in Turkish drug maker Bilim Ilac, sources familiar with the deal told Reuters.
European buyout firm Cinven with Turkish partner investor Actera and London-based Advent Venture Partners are also interested in the stake sale, which will be a billion-dollar transaction with high multiples, the sources said late on Thursday.
The size of the stake to be sold was not clear.
Bilim Ilac, which is the third biggest in the market in terms of revenue and box sales, was not immediately available to comment.
(Reporting by Seda Sezer and Ceyda Caglayan)